natgillin/translations-raw huggingface dataset:
14x1 film-coated tablet 28x1 film-coated tablet 30x1 film-coated tablet 50x1 film-coated tablet 84x1 film-coated tablet 90x1 film-coated tablet 100x1 film-coated tablet
14x1 filmsko obložena tableta 28x1 filmsko obložena tableta 30x1 filmsko obložena tableta 50x1 filmsko obložena tableta 84x1 filmsko obložena tableta 90x1 filmsko obložena tableta 100x1 filmsko obložena tableta
• Omeprazole, esomeprazole or cimetidine, medicines to treat upset stomach.
• omeprazol, esomeprazol ali cimetidin, zdravila za zdravljenje težav z želodcem,
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Koristi, ki so jih opazili pri uporabi klopidogrela, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovine za zniževanje lipidov, blokatorji beta in zaviralci angiotenzinske konvertaze).
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
Zanjo je značilna trombocitopenija in mikroangiopatična hemolitična anemija, povezana ali z nevrološkimi spremembami, motnjo v delovanju ledvic ali povišano telesno temperaturo.
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
V ACTIVE-A je bil delež hujših krvavitev v skupini s klopidogrelom + acetilsalicilno kislino večji kot v skupini s placebom + acetilsalicilno kislino (6,7 % v primerjavi s 4,3 %).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of bottles (30 or 100 film-coated tablets)
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLICA za stekleničke (30 ali 100 filmsko obloženih tablet)
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali acetilsalicilno kislino 325 mg/dan, spremljali so jih od 1 do 3 let.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR=23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR=7.3%; CI: -5.7 to 18.7 [p=0.258]).
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen (PAD)) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila značilno različna od acetilsalicilne kisline) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
Pri bolnikih, ki so ostali na zdravljenju do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel v kombinaciji z acetilsalicilno kislino in 6,3 % za placebo v kombinaciji z acetilsalicilno kislino.
Light pink to pink, capsule-shaped film-coated tablets debossed with “C75” on one side and plain on the other side.
Svetlo roza do roza filmsko obložene tablete v obliki kapsul, ki imajo na eni strani gladko površino, na drugi strani pa vtisnjeno oznako »C75«.
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Zaradi tega je potrebno nesteroidna protivnetna zdravila, vključno s COX-2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
The incidence of severe cases was similar for clopidogrel and ASA.
Incidenca hujših primerov je bila podobna za klopidogrel in za acetilsalicilno kislino.
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated castor oil Sodium laurilsulfate
Jedro tablete laktoza monohidrat mikrokristalna celuloza hidroksipropil celuloza (E463) krospovidon (tip A) hidrogenirano ricinusovo olje natrijev lavrilsulfat
• If you cut or injure yourself, it may take longer than usual for bleeding to stop.
• če se urežete ali poškodujete, se lahko krvavitev ustavi počasneje kot običajno.
In a small number of cases, bleeding in the eye, inside the head, the abdomen, the lung and the joints have also been reported.
V majhnem številu primerov so poročali tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih.
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4).
Peroralni antikoagulanti: sočasna uporaba klopidogrela in peroralnih antikoagulansov ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding.
Farmakodinamična interakcija med klopidogrelom in acetilsalicilno kislino je možna in lahko poveča tveganje za pojav krvavitev.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Acetilsalicilna kislina: acetilsalicilna kislina ni spremenila s klopidogrelom doseženega zaviranja agregacije trombocitov, ki je bila sprožena z ADP-jem, vendar je klopidogrel okrepil učinek acetilsalicilne kisline na s kolagenom sproženo agregacijo trombocitov.
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
Klopidogrel je v primerjavi z acetilsalicilno kislino značilno zmanjšal incidenco novih ishemičnih dogodkov (sestavljen opazovani dogodek miokardni infarkt, ishemična kap in žilna smrt).
However, if you are in any doubt, bleeding becomes serious or you experience unexpected bleeding from unusual parts of your body you should contact your doctor straight away (see section 2 ‘Warnings and precautions').
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih, če krvavitve postanejo resne ali se pojavijo krvavitve na neobičajnih mestih telesa (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
Then, the usual dose is one 75-mg tablet of Clopidogrel Teva Pharma B.V. per day
Nato je običajni odmerek ena 75-mg tableta zdravila Klopidogrel Teva Pharma B.V.
Risk Management Plan (RMP)
• Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
This includes any possible side effects not listed in this leaflet.
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso navedni v tem navodilu.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Zlasti post-hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, MI, možganska kap) in tudi značilno 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčnožilna smrt, MI, možganska kap ali neodzivna ishemija).
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Vendar pa so bolniki, ki so bili vključeni v klinična preskušanja klopidogrela, sočasno prejemali različna zdravila, vključno z diuretiki, blokatorji beta, zaviralci angiotenzinske konvertaze, kalcijevimi antagonisti, sredstvi za zmanjševanje ravni holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z inzulinom), antiepileptičnimi sredstvi in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično pomembnih neželenih interakcijah.
For minor cuts and injuries (e.g. shaving cuts) you should not worry.
Pri manjših urezninah ali poškodbah (npr. če se urežete pri britju), to navadno ni zaskrbljujoče.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs).
Kot pri drugih antitrombotikih je potrebno klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki se zdravijo z acetilsalicilno kislino, heparinom ali zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAID) vključno z zaviralci COX-2.
Clopidogrel should be given as a single daily dose of 75 mg.
• Odrasli in starostniki Klopidogrel je treba dajati kot enkratni dnevni odmerek 75 mg.
A serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body).
• resno obolenje, ki se imenuje trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki povzroči pojav številnih krvnih strdkov po celem telesu).
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
Bolezni živčevja intrakranialna krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezije, omotica motnje okušanja
Therefore, concomitant use should be undertaken with caution (see section 4.4).
Zato je pri sočasni uporabi potrebna previdnost (glejte poglavje 4.4).
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
V študijo COMMIT z 2x2 faktorsko raziskovalno zasnovo je bilo vključenih 45.852 bolnikov v 24 urah po nastopu simptomov, ki bi lahko kazali na miokardni infarkt in z neustreznimi vrednostmi EKG, ki so to potrjevale (elevacija ST spojnice, depresija ST spojnice ali levokračni blok).
Deutschland ratiopharm GmbH Tel: +49 731 402 02
Deutschland Teva GmbH Tel: +49 731 402 08
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
Možganska kap se je pojavila pri 296 (7,8 %) bolnikih, ki so prejemali klopidogrel + acetilsalicilno kislino, in pri 408 (10,8 %) bolnikih, ki so prejemali placebo + acetilsalicilno kislino (relativno zmanjšanje tveganja 28,4 %, 95 % IZ: od 16,8 % do 38,3 %, p = 0,00001).
• You should also tell your doctor immediately if you develop a medical condition (known as Thrombotic Thrombocytopenic Purpura) that includes altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas) (see section 4 ‘Possible Side Effects')
• morate zdravniku takoj povedati, če se pri vas pojavi bolezensko stanje (znano kot tombotična trombocitopenična purpura), ki vključuje spremembe vedenja, glavobol, komo, motnje vida, napade (krče), odpovedovanje ledvic, povišano telesno temperaturo, šibkost in krvavitev v trebuhu, črevesju ali na koži (vključno z drobnimi rdečimi pikami in večjimi odrgninami) (glejte poglavje 4 »Možni neželeni učinki«).
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.
V razvrstitvah pogostnosti so neželeni učinki navedeni po organskih sistemih in po padajoči resnosti.
Therefore clopidogrel should be used with caution in these patients (see section 4.2).
Zato je potrebno pri teh bolnikih klopidogrel uporabljati previdno (glejte poglavje 4.2).
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Sočasno dajanje klopidogrela s peroralnimi antikoagulansi ni priporočljivo, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
• Fever, signs of infection (e.g. sore throat), pale skin or extreme tiredness.
• povišana telesna temperatura, znaki okužbe (npr. vnetje grla), bledost kože ali huda utrujenost.
Warnings and precautions Tell your doctor before you start to take this medicine if:
Opozorila in previdnostni ukrepi Pred uporabo tega zdravila se posvetujte z zdravnikom v naslednjih primerih:
This could indicate that you are suffering from a serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body)
To lahko pomeni, da je pri vas prisotna trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki lahko povzroči pojav številnih krvnih strdkov po celem telesu).
Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%).
Hujše krvavitve so bile v obeh skupinah večinoma ekstrakranialne (5,3 % v skupini s klopidogrelom + acetilsalicilno kislino, 3,5 % v skupini s placebom + acetilsalicilno kislino), predvsem v prebavilih (3,5 % v prim.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Delež bolnikov s primarnim opazovanim dogodkom [srčno-žilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3 %) v skupini, zdravljeni s klopidogrelom, in 719 (11,4 %) v skupini, ki je prejemala placebo, to je 20 % zmanjšanje relativnega tveganja (95 % IZ od 10 % - 28 %; p=0,00009) v skupini, zdravljeni s klopidogrelom (17 % zmanjšanje relativnega tveganja, če so bili bolniki zdravljeni konzervativno, 29 % kadar je bila izvedena perkutana transluminalna koronarna angioplastika (PTKA) z ali brez stenta in 10 %, če je bila izvedena premostitvena operacija koronarnih arterij (POKA)).
What you need to know before you take Clopidogrel Teva Pharma B.V.
Kaj morate vedeti preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V.
If you suffer from hardening of the arteries (“atherosclerosis”) there is an increased risk of a blood clot forming in your blood vessels.
Če imate aterosklerozo (otrdele krvne žile), je pri vas prisotno povečano tveganje za nastanek krvnega strdka v krvnih žilah večje.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (udarni odmerek 300 mg, nato 75 mg/dan, n=6.259) ali skupino, ki je prejemala placebo (n=6.303), oboje prejeto v kombinaciji z acetilsalicilnsko kislino (75-325 mg enkrat na dan) in drugimi standardnimi terapijami.
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Qwave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
- Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
• Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound
• odrgnine, hematomi (neobičajne krvavitve pod kožo), krvavitve iz nosu, krvavitve iz želodca ali črevesja, povečane krvavitve na mestu vboda,
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z acetilsalicilno kislino (150 do 325 mg kot udarni odmerek, nato 75 do 162 mg na dan) in fibrinolitičnim sredstvom in po potrebi s heparinom.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide).
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), izpuščaj, eritematozni izpuščaj, urtikarija, ekcem, lichen planus
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini s klopidogrelom in 21,7 % bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p<0,001) v glavnem zaradi zmanjšanja pojavnosti zaradi infarkta zamašenih arterij.
- Keep this leaflet.
Previdno odlepite zadnjo stran.
• Altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas).
• spremembe vedenja, glavoboli, koma, motnje vida, napadi (krči), odpovedovanje ledvic, povišana telesna temperatura, huda utrujenost, šibkost ali krvavitve iz želodca, črevesja ali kože (vključno z manjšimi rdečimi madeži ali večjimi odrgninami).
Please note that instructions on how to remove the tablet from the blister strip are given on the outer carton of the peelable blisters.
• Navodila za odstranjevanje tablet iz pretisnega omota se nahajajo na škatlici, v katerem so shranjeni pretisni omoti, ki se odlepijo.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi po načelu začetnega namena zdravljenja so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala acetilsalicilno kislino, 1.020 dogodkov (zmanjšanje relativnega tveganja (zmanjšanje RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, pri dodatnih 10 [IZ: 0 do 20] bolnikih.
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA) - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
• odraslih bolnikih z akutnim koronarnim sindromom: akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Macrogol 4000
Filmska obloga laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) makrogol 4000 rdeči železov oksid (E172) rumeni železov oksid (E172)
Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide).
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Pri bolnikih je treba preveriti anamnezo preobčutljivosti na druge tienopiridine (kot sta npr. tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg na dan, n=22.961) ali placebo (n=22.891) v kombinaciji z acetilsalicilnsko kislino (162 mg na dan).
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + acetilsalicilna kislina, 0,7 % placebo + acetilsalicilna kislina) in hemoragičnih možganskih kapi (0,8 % v prim.
• Ticlopidine, other antiplatelet agent.
• tiklopidin, druga antiagregacijska zdravila.
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Pri ljudeh, ki so prejemali terapevtski odmerek klopidogrela, niso opazili nobenega učinka na jetrne presnovne encime.
Your doctor should have prescribed Clopidogrel Teva Pharma B.V. plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
If you become pregnant while taking Clopidogrel Teva Pharma B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon.
Pri podganah in pavijanih so poročali tudi o slabem želodčnem prenašanju (gastritis, želodčne erozije in/ali bruhanje), pri uporabi zelo velikih odmerkov.